- MiMedx (NASDAQ:MDXG) expects 2016 revenue of $245M-$255M, above a $241.9M consensus and good for 30%+ growth. EPS guidance of $0.31-$0.35 is above a $0.25 consensus. Gross margin guidance is at 87%-90%.
- Q1 guidance is for revenue of $53M-$55M and $0.06-$0.07 vs. a consensus of $53.2M and $0.05. Q4 revenue guidance of $49.5M-$52.5M and op. margin guidance of 14%-15% has been reiterated.
- SSO (surgical, sports medicine, and orthopedics) are expected to account for 26% of 2015 revenue, up from 2014's 21%. Starting in early 2016, MiMedx plans to "implement certain strategic initiatives to more intimately and aggressively focus on the market potential in SSO applications and procedures." The company also plans to increase its wound care salesforce by 25% in late 2015 and 2016.
- The company's buyback authorization has been hiked by $10M, bringing its total authorized funds since May 2014 to $60M.
- Shares have jumped to $9.04 after hours.